MARCO MASETTI

Email: marco_masetti@aosp.bo.it

Genere: Male

2/2015 - 1/2016: Assegnista di RIcerca

1/2012 - 12/2014: Dottorato di Ricerca in "Scienze Mediche Specialistiche"- tutor Dr. F. Grigioni

2/2013 - 1/2014: periodo di ricerca clinica su VAD e trapianto finanziato dall'Award ISHLT (International Society for Heart and Lung Transplantation) Early Career Award e dall'Università di Bologna, progeto "Marco Polo"; tutors: Prof. Andreas Zuckermann, Prof. Francesco Moscato, Prof. Daniel Zimpfer

8/2007 - 8/2011: Diploma di Specializzazione in Cardiologia

10/1999 - 3/2006: Laurea Specialistica in Medicina e Chirurgia

• inglese (C2)
• tedesco (B1)

• - Trapianto di cuore: gestione della terapia immunosoppressiva e valutazione dei pazienti candidati a trapianto cardiaco - LVAD: valutazione dei pazienti riferiti per impianto di LVAD, gestione medica e ambulatoriale post-impianto, analisi dati tecnici LVAD e ottimizzazione del dispositivo - Esecuzione di biopsie miocardiche per la diagnosi delle cardiomiopatie e del rigetto miocardico, di cateterismi cardiaci destri nei pazienti affetti da scompenso cardiaco e con LVAD (ramp test).

• Coinvolgimento in società scientifiche internazionali: - Membro ISHLT (International Society for Heart and Lung Transplantation); - Education Workforce Leader (2018-2021) del Junior Faculty and Trainee Council dell'ISHLT; - Membro dell'Abstract Selection Committee per il Meeting ISHLT 2018 - Liaison tra Heart Failure and Transplantation Council e Junior Faculty Council dell'ISHLT (2016-2018) - Membro del Program Committee per il Congresso ISHLT (2015); - Membro ESOT (European Society for Organ Transplantation) - Membro ISMCS (International Society for Mechanical Circulatory Support) - Socio SITO (Società Italiana Trapianti d'Organo)
• Vincitore dei seguenti Award: - ISHLT Transplant Registry Early Career Award (2016) , progetto: "Dissecting factors influencing post- transplant survival in patients transplanted with or without LVAD according to age and comorbidities: a step forward to optimize patients¿ selection and heart transplant benefit". - E-Factor1000 Grant-Heart Category, ricevuto da ECCTA (European Cardio Thoracic Transplant Association) 2016 all¿abstract ¿Trying to optimize heart transplant outcomes in older candidates: are all comorbidities created equal? presentato al Congresso ECCTA 2016, Barcellona - ISHLT International Travelling Scholarship Award¿ (2013) Project "Ventricular assist devices"; Vienna General Hospital (AKH), Herztransplantation Program, Tutor: Prof. A. Zuckermann; - City of Glasgow Award-Best Rapid Oral¿ assegnato all'abstract presentato al 15th Congress of the European Society for Organ Transplantation (ESOT)& 22nd Annual BSHI Conference, Glasgow, 2011
• 1. Loforte A, Fiorentino M, Gliozzi G, et al. ¿Heart transplant and hepato-renal dysfunction: the Model of End-Stage Liver Disease Excluding International Normalized Ratio as a predictor of postoperative outcomes¿. Transplant Proc. 2019 Nov, 51(9): 2962-66 2. Masetti M, Grigioni F. ¿LVAD and functional capacity: do we know how it works and what to do? ¿Eur J Prev Cardiol 2019 Nov;26 (17): 1803-1805; 3. Masetti M, Potena L. Liver and kidney function in heart failure: the narrow gate to achieve post-transplant survival. Clin Res Hepatol Gastroenterol. 2019 Apr;43(2): 115-116. 4. Goekler J, Zuckermann A, Kaider A, et al. ¿ Diminished impact of cytomegalovirus infection on graft vasculopathy development in the antiviral prophylaxis era- a retrospective study¿. Transpl Int. 2018 Aug;31(8):909-916; 5. Kransdorf EP, Mehta HS, Shah KB, et al. ¿ISHLT Transplant Registry: youthful investment-the path to progress¿, J Heart Lung Transplant. 2017 Oct;36(10):1027-1036; 6. Sabatino M, Vitale G, Manfredini V, Masetti M, et al: ¿Clinical relevance of the International Society for Heart and Lung Transplantation consensus classification of primary graft dysfunction after heart transplantation: Epidemiology, risk factors, and outcomes¿. J Heart Lung Transplant. 2017 Nov;36(11):1217-1225 7. Freystaetter K, Andreas M, et al. ¿The recipient¿s heme oxygenase-1 promoter region polymorphism is associated with cardiac allograft vasculopathy¿. Transpl Int. 2017 May; 30(5):510-518 8. Masetti M, Potena L: ¿Cholesterol efflux capacity: A weak player in the complex plot of cardiac allograft vasculopathy¿. J Heart Lung Transplant. 2016; 35 (11): 1286-88. 9. Granegger M, Masetti M, et al. ¿Continuous monitoring of aortic valve opening in rotary blood pump patients¿. IEEE Trans Biomed Eng 2016; 63 (6): 1201-07. 10. Potena L, Masetti M,et al. ¿Interplay of coronary angiography and intravascular ultrasound in predicting long-term outcomes after heart transplantation¿ J Heart Lung Transplant. 2015; 34 (9): 1146-53; 11. Potena L, Bontadini A, et al. ¿Occurence of fatal and nonfatal adverse outcomes after heart transplantation in patients with pretransplant noncytotoxic HLA antibodies¿ J Transplant. Jul 2013; 12. Masetti M, Potena L, et al: ¿Differential effect of everolimus on progression of early and late cardiac allograft vasculopathy in current clinical practice¿ Am J Transpl 2013 May; 13 (5):1217-26; 13. Potena L, Prestinenzi P, et al. ¿Cyclosporine lowering with everolimus versus mycophenolate mofetil in heart transplant recipients: long-term follow-up of the SHIRAKISS randomized, prospective study¿ J Heart Lung Transplant. 2012 Jun;31 (6):565-70 14. Potena L, Grigioni F, et al : ¿Safety and efficacy of early aggressive versus cholesterol driven lipid-lowering strategies in heart transplantation: A pilot, randomized, intravascular ultrasound study¿ J Heart Lung Transplant 2011 Dec;30(12):1305-11. 15. Potena L, Bianchi IG, Magnani G, Masetti M, et al: ¿Cyclosporine lowering with everolimus or mycophenolate to preserve renal function in heart recipients: a randomized study¿. Transplantation. 2010 Jan 27;89(2):263-5. 16. Sirri L, Potena L, Masetti M, et al: ¿Psychological predictors of mortality in heart transplanted patients: a prospective, 6-year follow-up study.¿ Transplantation. 2010 Apr 15;89(7):879-86 17. Potena L, Grigioni F, Masetti M, et al ¿Long-term effect of folic acid therapy in heart transplant recipients: follow-up analysis of a randomized study.¿ Transplantation. 2008 Apr 27;85(8):1146-50 18. Grigioni F, Potena L et al: ¿Potential of medical treatment, device therapy, and conventional surgery in patients referred for heart transplantation.¿ J Card Surg. 2007 Sep-Oct;22(5):456-8. 19. Sirri L, Potena L, Masetti M, et al: ¿Prevalence of substance-related disorders in heart transplantation candidates.¿ Transplant Proc. 2007 Jul-Aug;39(6):1970-2
• 1. Loforte A, Fiorentino M, Gliozzi G, et al. ¿Heart transplant and hepato-renal dysfunction: the Model of End-Stage Liver Disease Excluding International Normalized Ratio as a predictor of postoperative outcomes¿. Transplant Proc. 2019 Nov, 51(9): 2962-66 2. Masetti M, Grigioni F. ¿LVAD and functional capacity: do we know how it works and what to do? ¿Eur J Prev Cardiol 2019 Nov;26 (17): 1803-1805; 3. Masetti M, Potena L. Liver and kidney function in heart failure: the narrow gate to achieve post-transplant survival. Clin Res Hepatol Gastroenterol. 2019 Apr;43(2): 115-116. 4. Goekler J, Zuckermann A, Kaider A, et al. ¿ Diminished impact of cytomegalovirus infection on graft vasculopathy development in the antiviral prophylaxis era- a retrospective study¿. Transpl Int. 2018 Aug;31(8):909-916; 5. Kransdorf EP, Mehta HS, Shah KB, et al. ¿ISHLT Transplant Registry: youthful investment-the path to progress¿, J Heart Lung Transplant. 2017 Oct;36(10):1027-1036; 6. Sabatino M, Vitale G, Manfredini V, Masetti M, et al: ¿Clinical relevance of the International Society for Heart and Lung Transplantation consensus classification of primary graft dysfunction after heart transplantation: Epidemiology, risk factors, and outcomes¿. J Heart Lung Transplant. 2017 Nov;36(11):1217-1225 7. Freystaetter K, Andreas M, et al. ¿The recipient¿s heme oxygenase-1 promoter region polymorphism is associated with cardiac allograft vasculopathy¿. Transpl Int. 2017 May; 30(5):510-518 8. Masetti M, Potena L: ¿Cholesterol efflux capacity: A weak player in the complex plot of cardiac allograft vasculopathy¿. J Heart Lung Transplant. 2016; 35 (11): 1286-88. 9. Granegger M, Masetti M, et al. ¿Continuous monitoring of aortic valve opening in rotary blood pump patients¿. IEEE Trans Biomed Eng 2016; 63 (6): 1201-07. 10. Potena L, Masetti M,et al. ¿Interplay of coronary angiography and intravascular ultrasound in predicting long-term outcomes after heart transplantation¿ J Heart Lung Transplant. 2015; 34 (9): 1146-53; 11. Potena L, Bontadini A, et al. ¿Occurence of fatal and nonfatal adverse outcomes after heart transplantation in patients with pretransplant noncytotoxic HLA antibodies¿ J Transplant. Jul 2013; 12. Masetti M, Potena L, et al: ¿Differential effect of everolimus on progression of early and late cardiac allograft vasculopathy in current clinical practice¿ Am J Transpl 2013 May; 13 (5):1217-26; 13. Potena L, Prestinenzi P, et al. ¿Cyclosporine lowering with everolimus versus mycophenolate mofetil in heart transplant recipients: long-term follow-up of the SHIRAKISS randomized, prospective study¿ J Heart Lung Transplant. 2012 Jun;31 (6):565-70 14. Potena L, Grigioni F, et al : ¿Safety and efficacy of early aggressive versus cholesterol driven lipid-lowering strategies in heart transplantation: A pilot, randomized, intravascular ultrasound study¿ J Heart Lung Transplant 2011 Dec;30(12):1305-11. 15. Potena L, Bianchi IG, Magnani G, Masetti M, et al: ¿Cyclosporine lowering with everolimus or mycophenolate to preserve renal function in heart recipients: a randomized study¿. Transplantation. 2010 Jan 27;89(2):263-5. 16. Sirri L, Potena L, Masetti M, et al: ¿Psychological predictors of mortality in heart transplanted patients: a prospective, 6-year follow-up study.¿ Transplantation. 2010 Apr 15;89(7):879-86 17. Potena L, Grigioni F, Masetti M, et al ¿Long-term effect of folic acid therapy in heart transplant recipients: follow-up analysis of a randomized study.¿ Transplantation. 2008 Apr 27;85(8):1146-50 18. Grigioni F, Potena L et al: ¿Potential of medical treatment, device therapy, and conventional surgery in patients referred for heart transplantation.¿ J Card Surg. 2007 Sep-Oct;22(5):456-8. 19. Sirri L, Potena L, Masetti M, et al: ¿Prevalence of substance-related disorders in heart transplantation candidates.¿ Transplant Proc. 2007 Jul-Aug;39(6):1970-2